Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 6/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | IDE | P14735 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439518 | 0.97 | HLCS (0.67) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL6884034 | 0.89 | HLCS (0.65) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL2514439 | 0.88 | TDP1 (0.67) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL3120163 | 0.88 | TDP1 (0.54) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL2513356 | 0.88 | TDP1 (0.67) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL8578177 | 0.88 | TDP1 (0.54) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL9241448 | 0.88 | TDP1 (0.61) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL4295408 | 0.87 | TDP1 (0.52) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL6883588 | 0.87 | TDP1 (0.52) | HLCSTDP1MEN1ABL1LMNA | |
| Biotin SCHEMBL27497286 | 0.86 | TDP1 (0.56) | HLCSTDP1MEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084475-B2 | Methods for site specific conjugation of proteins containing glycosylated Fc domains | JANSSEN BIOTECH, INC. (US) | 2024-09-10 | — | — | US | claimed |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250206844-A1 | SITE-SPECIFIC CONJUGATION OF GLYCOSYLATED MONOCLONAL ANTIBODIES WITH TRANSGLUTAMINASE | JANSSEN BIOTECH, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250188187-A1 | SITE-SPECIFIC CONJUGATION OF GLYCOSYLATED MONOCLONAL ANTIBODIES WITH TRANSGLUTAMINASE | JANSSEN BIOTECH, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12227593-B2 | Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase | JANSSEN BIOTECH, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240384002-A1 | METHODS FOR SITE SPECIFIC CONJUGATION OF PROTEINS CONTAINING GLYCOSYLATED Fc DOMAINS | JANSSEN BIOTECH, INC. | 2024-11-21 | — | — | US | disclosed |
| US-12084475-B2 | Methods for site specific conjugation of proteins containing glycosylated Fc domains | JANSSEN BIOTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4153619-A2 | SITE-SPECIFIC CONJUGATION OF GLYCOSYLATED MONOCLONAL ANTIBODIES WITH TRANSGLUTAMINASE | Janssen Biotech, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153632-A1 | METHODS FOR SITE SPECIFIC CONJUGATION OF PROTEINS CONTAINING GLYCOSYLATED FC DOMAINS | Janssen Biotech, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| US-11168321-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| CN-107916456-B | Method for generating and screening libraries encoded by DNA | X-化学有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-20200385709-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3211126-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X CHEM INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3653763-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-Chem, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3211126-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-Chem, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2396459-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160369267-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9359601-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20120053091-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2012-03-01 | — | — | US | disclosed |
| WO-2010094036-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168321-B2 | Methods of creating and screening DNA-encoded libraries | PCNA, DNA2, POLM | HLCS 245/4885TDP1 129/4885MEN1 1399/4885 |
| US-20200385709-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PCNA, DNA2, POLM | HLCS 245/4885TDP1 129/4885MEN1 1399/4885 |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | PCNA, DNA2, POLM | HLCS 324/4885TDP1 202/4885MEN1 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.